$0.74
▼ -0.2% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
Overview
52-week range
$0.46
$7.20
4% of range
Avg surprise (last 3)
+12.6%
Avg reaction (last 2)
+2.9%
50% positive
Latest IV / EM
251%
EM ±18.1% · $1 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.22 | $-0.28 | +21.4% | +38.9% | +6.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.52 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.40 | $-0.40 | 0.0% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.36 | $-0.43 | +16.3% | — | -0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.50 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.36 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.01 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.82 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.11 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.33 | -$0.40 | +17.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-6M | — | $-6M | $-7M | $-6M | — | $-6M | $-7M |
| Net income | $5M | — | $-8M | $-6M | $-5M | — | $-6M | $-4M |
| EPS (diluted) | $0.30 | — | $-0.52 | $-0.40 | $-0.36 | — | $-0.50 | $-0.36 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8M | $12M | $5M | $6M | $13M | $8M | $9M | $5M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $9M | $14M | $15M | $19M | $25M | $20M | $16M | $20M |
| Total assets | $9M | $14M | $15M | $19M | $25M | $20M | $16M | $21M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $10M | $20M | $15M | $13M | $14M | $5M | $7M | $7M |
| Total equity | $-1M | $-7M | $-268,000 | $6M | $11M | $14M | $9M | $14M |